Laboratory comparison of the VisuLize IX antigen assay with the asserachrome IX antigen assay

Kim A. Janatpour, Robert C. Gosselin, John T Owings, Edward C. Larkin

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Factor IX antigen levels are used primarily to assess factor IX levels in patients with liver insufficiency or who are receiving oral vitamin K antagonist therapy. We evaluated the test performance of a new factor IX antigen enzyme-linked immunoassay kit and compared it to our currently used enzyme-linked immunoassay method. Samples from normal donors and patients with known hemophilia B of varying severity were tested by using a predicate factor IX antigen method (Asserachachrome IX:Ag) and a new factor IX antigen method (VisuLize IX Antigen). The 2 methods were evaluated for performance, correlation, differences, and bias. Test samples included 46 normal donors, 14 commercial products, and 16, 18, and 15 severe, moderate, and mildly deficient factor IX deficient plasmas, respectively The 2 methods correlated well using regression analysis. However, there were significant differences using the paired test with bias plots indicating higher absolute values for the VisuLize IX antigen method in the severe and moderate deficiency range, but not the normal range. Testing commercially prepared survey material, the Asserachrome method demonstrated a consistently lower result than expected. The VisuLize factor IX is a new method for determining antigenic levels in human plasma. This method has a much shorter incubation time and demonstrates good correlation with current factor IX antigenic method.

Original languageEnglish (US)
Pages (from-to)152-155
Number of pages4
JournalLaboratory Hematology
Volume12
Issue number3
DOIs
StatePublished - 2006

Fingerprint

Factor IX
Assays
Antigens
Immunoenzyme Techniques
Plasma (human)
Vitamin K
Tissue Donors
Hepatic Insufficiency
Enzymes
Hemophilia B
Regression analysis
Liver
Plasmas
Reference Values
Regression Analysis
Testing

Keywords

  • Factor IX antigen

ASJC Scopus subject areas

  • Hematology

Cite this

Laboratory comparison of the VisuLize IX antigen assay with the asserachrome IX antigen assay. / Janatpour, Kim A.; Gosselin, Robert C.; Owings, John T; Larkin, Edward C.

In: Laboratory Hematology, Vol. 12, No. 3, 2006, p. 152-155.

Research output: Contribution to journalArticle

Janatpour, Kim A. ; Gosselin, Robert C. ; Owings, John T ; Larkin, Edward C. / Laboratory comparison of the VisuLize IX antigen assay with the asserachrome IX antigen assay. In: Laboratory Hematology. 2006 ; Vol. 12, No. 3. pp. 152-155.
@article{51449e775dad47da92cc19ae4779b995,
title = "Laboratory comparison of the VisuLize IX antigen assay with the asserachrome IX antigen assay",
abstract = "Factor IX antigen levels are used primarily to assess factor IX levels in patients with liver insufficiency or who are receiving oral vitamin K antagonist therapy. We evaluated the test performance of a new factor IX antigen enzyme-linked immunoassay kit and compared it to our currently used enzyme-linked immunoassay method. Samples from normal donors and patients with known hemophilia B of varying severity were tested by using a predicate factor IX antigen method (Asserachachrome IX:Ag) and a new factor IX antigen method (VisuLize IX Antigen). The 2 methods were evaluated for performance, correlation, differences, and bias. Test samples included 46 normal donors, 14 commercial products, and 16, 18, and 15 severe, moderate, and mildly deficient factor IX deficient plasmas, respectively The 2 methods correlated well using regression analysis. However, there were significant differences using the paired test with bias plots indicating higher absolute values for the VisuLize IX antigen method in the severe and moderate deficiency range, but not the normal range. Testing commercially prepared survey material, the Asserachrome method demonstrated a consistently lower result than expected. The VisuLize factor IX is a new method for determining antigenic levels in human plasma. This method has a much shorter incubation time and demonstrates good correlation with current factor IX antigenic method.",
keywords = "Factor IX antigen",
author = "Janatpour, {Kim A.} and Gosselin, {Robert C.} and Owings, {John T} and Larkin, {Edward C.}",
year = "2006",
doi = "10.1532/LH96.06011",
language = "English (US)",
volume = "12",
pages = "152--155",
journal = "Laboratory Hematology",
issn = "1080-2924",
publisher = "Carden Jennings Publishing Co. Ltd",
number = "3",

}

TY - JOUR

T1 - Laboratory comparison of the VisuLize IX antigen assay with the asserachrome IX antigen assay

AU - Janatpour, Kim A.

AU - Gosselin, Robert C.

AU - Owings, John T

AU - Larkin, Edward C.

PY - 2006

Y1 - 2006

N2 - Factor IX antigen levels are used primarily to assess factor IX levels in patients with liver insufficiency or who are receiving oral vitamin K antagonist therapy. We evaluated the test performance of a new factor IX antigen enzyme-linked immunoassay kit and compared it to our currently used enzyme-linked immunoassay method. Samples from normal donors and patients with known hemophilia B of varying severity were tested by using a predicate factor IX antigen method (Asserachachrome IX:Ag) and a new factor IX antigen method (VisuLize IX Antigen). The 2 methods were evaluated for performance, correlation, differences, and bias. Test samples included 46 normal donors, 14 commercial products, and 16, 18, and 15 severe, moderate, and mildly deficient factor IX deficient plasmas, respectively The 2 methods correlated well using regression analysis. However, there were significant differences using the paired test with bias plots indicating higher absolute values for the VisuLize IX antigen method in the severe and moderate deficiency range, but not the normal range. Testing commercially prepared survey material, the Asserachrome method demonstrated a consistently lower result than expected. The VisuLize factor IX is a new method for determining antigenic levels in human plasma. This method has a much shorter incubation time and demonstrates good correlation with current factor IX antigenic method.

AB - Factor IX antigen levels are used primarily to assess factor IX levels in patients with liver insufficiency or who are receiving oral vitamin K antagonist therapy. We evaluated the test performance of a new factor IX antigen enzyme-linked immunoassay kit and compared it to our currently used enzyme-linked immunoassay method. Samples from normal donors and patients with known hemophilia B of varying severity were tested by using a predicate factor IX antigen method (Asserachachrome IX:Ag) and a new factor IX antigen method (VisuLize IX Antigen). The 2 methods were evaluated for performance, correlation, differences, and bias. Test samples included 46 normal donors, 14 commercial products, and 16, 18, and 15 severe, moderate, and mildly deficient factor IX deficient plasmas, respectively The 2 methods correlated well using regression analysis. However, there were significant differences using the paired test with bias plots indicating higher absolute values for the VisuLize IX antigen method in the severe and moderate deficiency range, but not the normal range. Testing commercially prepared survey material, the Asserachrome method demonstrated a consistently lower result than expected. The VisuLize factor IX is a new method for determining antigenic levels in human plasma. This method has a much shorter incubation time and demonstrates good correlation with current factor IX antigenic method.

KW - Factor IX antigen

UR - http://www.scopus.com/inward/record.url?scp=33748598264&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748598264&partnerID=8YFLogxK

U2 - 10.1532/LH96.06011

DO - 10.1532/LH96.06011

M3 - Article

C2 - 16950677

AN - SCOPUS:33748598264

VL - 12

SP - 152

EP - 155

JO - Laboratory Hematology

JF - Laboratory Hematology

SN - 1080-2924

IS - 3

ER -